undamentalytics Newsletter
Sign in

UFP Technologies Inc (UFPT) stock

Add to watchlist

Add holding +

NASDAQ: UFPT Nasdaq Health Care Supplies Next results ~November 3, 2026

C+ Fundamentals grade

UFP Technologies Inc is a US-listed company in the health care supplies industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$220

Cash-flow model

Base case. Range ~$160–$300 across our lower- and higher-growth cases (7.6%–17.6% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 27% above our base value.

Price used: $282.89, November 3, 2026

UFP Technologies Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 27 sales by directors and officers, last 12 monthsInsider trades
  • Funds132 adding, 128 cuttingOf 31 active managers that changed their stake, 15 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter UFP Technologies files

Where UFP Technologies stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $632m, up 7.3% on a year earlier, slower than the 11.2% growth a quarter earlier. That growth ranks 3 of 11 among the health care supplies companies we cover. Free-cash-flow margin fell to 9.0% from 12.3% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 6 of our 7 financial-health checks. Our cash-flow model value is $235 a share, against a share price of $293. At that price, our model says the market is pricing in about 16.3% a year of cash-flow growth for five years, slower than the 25.1% a year revenue growth it has delivered.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

UFP Technologies Inc's trailing-twelve-month revenue grew 7.3% year on year, with a free-cash-flow margin of 9.0%. Where it stands out: revenue growth of 7.3% ranks 3 of 13 health care supplies companies we cover. Where it lags: gross margin of 28.5% ranks 13 of 13 health care supplies companies we cover.

Our discounted-cash-flow model values the business at ~$220 per share in the base case (~$160–$300 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 21.6% while net income grew 7.7%: a 29pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Priced above our value. The share price of $283.97 is 22% above our value per share of $220.
  • Volatile shares. Over the past year the shares showed annualised volatility of 49% and a beta of 1.3 against the S&P 500.
  • Insiders selling. 7 insiders sold $14M of stock over the past 365 days and none bought (0% under pre-set trading plans).
  • Growth easing. The growth rate is 3.9 points lower than a quarter earlier.
  • Weak cash conversion. Free cash flow was 79% of net income over the last 12 months.
  • Below peers: gross margin. Gross margin of 28.5% ranks 13 of 13 health care supplies companies we cover (median 52.9%).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$2.92 against an average estimate of $2.56: beat by 14.2%
Revenue
$174m, up 15.1% on a year earlier
Share reaction
+31.4% in the first session after the results on August 3, 2026, against +3.3% for the S&P 500
Next report
November 3, 2026; average EPS estimate $2.69

UFP Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.4%
  • 1 week-4.1%
  • 1 month-5.9%
  • This year+27.9%
  • 1 year+42.1%
  • 5 years+335.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$632M
Operating margin
15.3%
Net margin
11.4%
EPS (TTM, diluted)
$9.25

Growth

Revenue growth
+7.3%
Change in growth rate
−3.9 pts
Share count change
+0.2%

Cash

Free cash flow (TTM)
$56.9M
FCF margin
9.0%
Stock pay % of revenue
1.6%

Earnings

Last results
August 3, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Insider trade
  3. Announcement
  4. Insider trade
  5. Insider trade
  6. Insider trade
  7. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

UFP Technologies Inc valuation models and calculator

What the price is pricing in

The share price implies about 15.6% a year of cash-flow growth for five years.That is slower than the 25.1% a year revenue growth UFP Technologies has delivered.

  • Priced in15.6%
  • Last 12 months7.3%
  • 3 years a year17.8%
  • 5 years a year25.1%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($282.79, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$220
Price used
$282.79close November 3, 2026
Implied change
▼ 21%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of UFP Technologies Inc's free cash flow after stock-based pay with after-tax interest added back ($64.3M, FY2026 Q2 TTM), growing 9.3% and 10.9% in the next two years (forecasts, guidance and its record), then back to 12.6% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$160–~$300 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of UFP Technologies Inc's free cash flow after stock-based pay ( $64.3M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value UFP Technologies Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.05 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$220 ~$160–$300 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$120 ~$130–$240 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$150 ~$100–$220 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$130 ~$110–$150 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$170 ~$120–$220 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare UFP Technologies Inc with Health Care Supplies in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −27%
  • Revenue growth 5 points higher ▲ +35%
  • Free-cash-flow margin 1 point lower ▼ −11%
  • Last year's free-cash-flow margin change, if it persists ▼ −26%
  • Discount rate 1 point higher ▼ −16%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $106$149$205$280$378$504
8.5% $78$109$150$203$273$362
10% $61$85$116$157$210$278

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$23.82$25.45$27.80$30.04$49.61$46.60$70.26$117.89$172.04$244.51$222.03$283.97
Market value$172m$185m$204m$223m$373m$353m$535m$903m$1.3bn$1.9bn$1.7bn$2.2bn
+ Net debt (− = net cash)−$28m−$31m−$38m$22m$11m−$24m$64m$51m$27m$176m$115m$108m
Enterprise value$144m$155m$166m$245m$384m$328m$599m$954m$1.4bn$2.1bn$1.8bn$2.3bn
Multiples
Price / sales 1.2x1.3x1.4x1.2x1.9x2.0x2.6x2.6x3.3x3.8x2.9x3.5x
Price / earnings 22.6x23.2x22.1x15.6x18.9x26.4x33.7x21.6x29.5x32.3x25.4x30.7x
Price / free cash flow —88.2x28.8x14.0x14.7x17.1x60.1xn/m43.0x33.4x18.9x31.0x
EV / EBITDA 8.7x8.7x9.6x8.9x11.7x13.1x20.2x14.2x19.6x21.7x16.6x21.0x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

60 /100

Moderate moat

How hard UFP Technologies's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 14 / 20

    Cash operating profit has been a median 11.0% of total assets over 7 years.

  • Pricing power 10 / 20

    Gross margin has been a median 26.3%, moving by 1.7 percentage points (standard deviation) across 10 years.

  • Durability 12 / 20

    Operating margin has been a median 11.4%; its worst year was 7.8%.

  • Cash conversion 14 / 20

    Free cash flow was positive in 9 of 10 years, at a median 9.5% of revenue.

  • Discipline 16 / 20

    The diluted share count rose 3.0% over five years; stock-based pay has been a median 1.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (65 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $167m and EPS of $2.69 (range $2.57 to $2.78) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $10.62 +9% $658m +9%
Next $11.87 +12% $699m +6%

Next year's EPS estimate has moved +1.6% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.3% on 90 days ago. In the last 30 days, 3 analysts raised UFP Technologies Inc's forecast and 0 cut it.

Consensus EPS forecast UFP Technologies Inc, last 90 days
$10.00 $10.50 $11.00 $11.50 $12.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $10.38 Current fiscal year, 60 days ago: $10.62 Current fiscal year, 30 days ago: $10.62 Current fiscal year, 7 days ago: $10.62 Current fiscal year, Now: $10.62 $10.62 Next fiscal year, 90 days ago: $11.69 Next fiscal year, 60 days ago: $11.87 Next fiscal year, 30 days ago: $11.87 Next fiscal year, 7 days ago: $11.87 Next fiscal year, Now: $11.87 $11.87

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $10.38$11.69
60 days ago $10.62$11.87
30 days ago $10.62$11.87
7 days ago $10.62$11.87
Now $10.62$11.87

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $2.56 $2.92 +14.2%
Mar 2026 $2.31 $2.48 +7.4%
Dec 2025 $2.23 $2.44 +9.2%
Sept 2025 $2.17 $2.39 +10.0%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows UFP Technologies Inc's revenue by +9.3% next year and +10.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+7.4%, weight 62%) and the company's own record (+12.6%, weight 38%) . How the weights are set.

Analyst recommendations

4 analysts, Oct 2026
Buy250%
Hold250%
Sell00%

Monthly trend

  1. Oct 20261124
  2. Sep 20261124
  3. Aug 20261124

Counts of recommendations published by analysts covering UFP Technologies Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
17.6%
of tradable shares
Days to cover
8.62
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
3.8%
of shares
Employees
4,846
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +47.4%

$192.64 on October 31, 2025 to $283.97

ThenNowEffect
Revenue (last 12 months) $589m $632m +7.3%
Net margin 11.4% 11.4% +0.4%
P/E multiple 22.4x 30.7x +37.1%
Share count 8m 8m −0.2%

Biggest factor: p/e multiple.

Last 3 years +98.3%

$143.17 on November 3, 2023 to $283.97

ThenNowEffect
Revenue (last 12 months) $386m $632m +63.6%
Net margin 12.9% 11.4% −11.0%
P/E multiple 22.2x 30.7x +38.2%
Share count 8m 8m −1.5%

Biggest factor: revenue.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
UFPT+51%+68%+46%+42%−9%+28%
Industry peers (median)+13%−50%+22%−13%−20%−19%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
UFPT83%67%67%58%42%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
UFPT−15%−24%−33%−33%−35%−31%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 48% from September 20, 2024 to October 30, 2025. Getting back needed a 93% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$185.45 – $334.84
From 52-week high
−15.2%
vs 50-day average
−2.5%
vs 200-day average
+13.9%
Volatility (1 year)
49%
Beta vs S&P 500
1.31

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±9.7%
After a week
7 up, 5 down
typical move ±13.5%
After a month
8 up, 4 down
typical move ±15.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 3, 2026 +31.4% +3.3% +27.6% +15.4%
May 4, 2026 +9.5% +0.4% +14.4% +12.5%
February 24, 2026 −0.7% +1.6% −16.1% −21.4%
November 3, 2025 +15.8% −1.0% +21.7% +14.0%
August 5, 2025 −5.6% +0.3% −2.9% −7.7%
May 7, 2025 +6.6% +1.1% +10.7% +8.2%
February 25, 2025 −2.1% −0.4% −11.6% −15.5%
November 12, 2024 −8.3% −0.3% −15.4% −21.7%
August 2, 2024 −8.0% −4.7% −5.0% +0.5%
May 1, 2024 +24.0% +0.6% +22.3% +26.4%
February 26, 2024 −2.2% −0.2% +2.5% +14.3%
November 9, 2023 +2.1% +0.8% +12.4% +23.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

UFP Technologies Inc in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) UFP Technologies Inc
$300M $400M $500M $600M $700M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $389.8M Revenue (TTM), FY23 Q4: $400.1M Revenue (TTM), FY24 Q1: $407.3M Revenue (TTM), FY24 Q2: $417.5M Revenue (TTM), FY24 Q3: $461.8M Revenue (TTM), FY24 Q4: $504.4M Revenue (TTM), FY25 Q1: $547.6M Revenue (TTM), FY25 Q2: $588.6M Revenue (TTM), FY25 Q3: $598M Revenue (TTM), FY25 Q4: $602.8M Revenue (TTM), FY26 Q1: $608.9M Revenue (TTM), FY26 Q2: $631.6M $631.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $389.8M
FY23 Q4 $400.1M
FY24 Q1 $407.3M
FY24 Q2 $417.5M
FY24 Q3 $461.8M
FY24 Q4 $504.4M
FY25 Q1 $547.6M
FY25 Q2 $588.6M
FY25 Q3 $598M
FY25 Q4 $602.8M
FY26 Q1 $608.9M
FY26 Q2 $631.6M
Revenue growth, TTM YoY UFP Technologies Inc
0% 20% 40% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 22.2% Revenue growth, TTM YoY, FY23 Q4: 13.1% Revenue growth, TTM YoY, FY24 Q1: 7.1% Revenue growth, TTM YoY, FY24 Q2: 8.2% Revenue growth, TTM YoY, FY24 Q3: 18.5% Revenue growth, TTM YoY, FY24 Q4: 26.1% Revenue growth, TTM YoY, FY25 Q1: 34.4% Revenue growth, TTM YoY, FY25 Q2: 41.0% Revenue growth, TTM YoY, FY25 Q3: 29.5% Revenue growth, TTM YoY, FY25 Q4: 19.5% Revenue growth, TTM YoY, FY26 Q1: 11.2% Revenue growth, TTM YoY, FY26 Q2: 7.3% 7.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 22.2%
FY23 Q4 13.1%
FY24 Q1 7.1%
FY24 Q2 8.2%
FY24 Q3 18.5%
FY24 Q4 26.1%
FY25 Q1 34.4%
FY25 Q2 41.0%
FY25 Q3 29.5%
FY25 Q4 19.5%
FY26 Q1 11.2%
FY26 Q2 7.3%
Operating margin (TTM) UFP Technologies Inc
14% 14.5% 15% 15.5% 16% 16.5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 14.3% Operating margin (TTM), FY23 Q4: 14.4% Operating margin (TTM), FY24 Q1: 14.9% Operating margin (TTM), FY24 Q2: 14.8% Operating margin (TTM), FY24 Q3: 15.5% Operating margin (TTM), FY24 Q4: 16.0% Operating margin (TTM), FY25 Q1: 16.1% Operating margin (TTM), FY25 Q2: 16.1% Operating margin (TTM), FY25 Q3: 15.6% Operating margin (TTM), FY25 Q4: 15.3% Operating margin (TTM), FY26 Q1: 15.2% Operating margin (TTM), FY26 Q2: 15.3% 15.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 14.3%
FY23 Q4 14.4%
FY24 Q1 14.9%
FY24 Q2 14.8%
FY24 Q3 15.5%
FY24 Q4 16.0%
FY25 Q1 16.1%
FY25 Q2 16.1%
FY25 Q3 15.6%
FY25 Q4 15.3%
FY26 Q1 15.2%
FY26 Q2 15.3%
FCF margin (TTM) UFP Technologies Inc
6% 8% 10% 12% 14% 16% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 9.2% FCF margin (TTM), FY23 Q4: 7.7% FCF margin (TTM), FY24 Q1: 9.9% FCF margin (TTM), FY24 Q2: 10.3% FCF margin (TTM), FY24 Q3: 9.8% FCF margin (TTM), FY24 Q4: 11.3% FCF margin (TTM), FY25 Q1: 10.8% FCF margin (TTM), FY25 Q2: 12.3% FCF margin (TTM), FY25 Q3: 14.7% FCF margin (TTM), FY25 Q4: 12.1% FCF margin (TTM), FY26 Q1: 10.6% FCF margin (TTM), FY26 Q2: 9.0% 9.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 9.2%
FY23 Q4 7.7%
FY24 Q1 9.9%
FY24 Q2 10.3%
FY24 Q3 9.8%
FY24 Q4 11.3%
FY25 Q1 10.8%
FY25 Q2 12.3%
FY25 Q3 14.7%
FY25 Q4 12.1%
FY26 Q1 10.6%
FY26 Q2 9.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 99 121 127 131 139 139 139 146 148 190 198 179 206 354 400 504 603 632
Gross profit 27 35 36 38 41 37 37 35 35 48 54 45 51 90 112 147 170 180
EBITDA 11 18 18 20 21 16 17 18 17 27 33 25 30 67 69 96 111 111
Operating income 8 14 16 17 17 12 12 12 12 20 25 17 21 55 58 81 92 96
Net income 6 9 10 11 11 8 8 8 9 14 20 13 16 42 45 59 68 72
Diluted EPS $0.94 $1.37 $1.48 $1.55 $1.59 $1.05 $1.05 $1.10 $1.26 $1.93 $2.63 $1.77 $2.09 $5.45 $5.83 $7.58 $8.75 $9.25
Growth (year on year)
Revenue — +21.7% +5.4% +2.9% +6.3% +0.1% −0.3% +5.2% +1.2% +28.8% +4.2% −9.6% +15.0% +71.5% +13.1% +26.1% +19.5% +7.3%
EBITDA — +58.2% +5.4% +5.9% +9.6% −25.8% +3.9% +7.9% −3.0% +58.4% +19.8% −24.0% +18.5% +127.1% +2.7% +38.4% +16.6% −1.3%
Operating income — +75.7% +9.2% +6.0% +4.4% −33.5% +1.3% +4.5% −4.4% +67.7% +26.0% −32.3% +26.8% +161.1% +4.1% +40.3% +14.1% +2.0%
Net income — +56.0% +11.9% +5.3% +3.5% −33.0% +0.4% +5.0% +15.6% +55.4% +38.0% −32.3% +18.8% +163.1% +7.5% +31.3% +15.8% +7.7%
Diluted EPS — +45.7% +8.0% +4.7% +2.6% −34.0% 0.0% +4.8% +14.5% +53.2% +36.3% −32.7% +18.1% +160.8% +7.0% +30.0% +15.4% +7.6%
Margins
Gross margin 26.9% 28.7% 28.5% 29.3% 29.5% 26.5% 27.0% 23.7% 24.0% 25.4% 27.2% 24.9% 24.8% 25.5% 28.1% 29.1% 28.3% 28.5%
EBITDA margin 11.2% 14.5% 14.5% 15.0% 15.4% 11.4% 11.9% 12.2% 11.7% 14.4% 16.6% 13.9% 14.4% 19.0% 17.3% 19.0% 18.5% 17.6%
Operating margin 8.3% 11.9% 12.4% 12.7% 12.5% 8.3% 8.4% 8.4% 7.9% 10.3% 12.5% 9.3% 10.3% 15.7% 14.4% 16.0% 15.3% 15.3%
Net margin 6.0% 7.7% 8.1% 8.3% 8.1% 5.4% 5.5% 5.5% 6.2% 7.5% 10.0% 7.5% 7.7% 11.8% 11.2% 11.7% 11.3% 11.4%
Free-cash-flow margin 8.9% 7.1% 6.3% 3.2% 7.4% −1.7% −2.3% 1.4% 4.8% 8.3% 12.8% 11.5% 4.3% 1.1% 7.7% 11.3% 15.2% 11.3%
Cash flow
Cash from operations 11 12 12 16 16 11 13 9 17 21 31 25 14 18 41 67 92 72
Capital spending 2 3 4 12 6 13 16 7 10 5 6 4 5 14 10 10 0 0
Free cash flow 9 9 8 4 10 −2 −3 2 7 16 25 21 9 4 31 57 92 72
Stock-based pay 1 1 1 1 1 1 1 1 1 1 2 2 2 3 5 7 9 10
Free cash flow after stock pay 8 8 7 3 9 −3 −4 1 6 15 24 19 6 1 26 50 83 61
Balance sheet
Cash 13 22 30 33 37 34 30 31 38 3 4 24 11 4 5 13 20 9
Total debt 0 8 6 10 4 3 2 1 — 25 15 0 75 55 32 189 135 117
Net debt (negative = net cash) −13 −15 −24 −24 −33 −31 −28 −31 −38 22 11 −24 64 51 27 176 115 108
Diluted shares 6m 7m 7m 7m 7m 7m 7m 7m 7m 7m 8m 8m 8m 8m 8m 8m 8m 8m
Returned to shareholders
Buybacks — — — — — — 1 — — — — — — — — — — —
Total returned — — — — — — 1 — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · June 30, 2026
What it owns · $682m
Short-term assets $235mLonger-term assets $447m
What it owes, and who funded it · $682m
Short-term liabilities $78mLonger-term liabilities $141mShareholders' equity $462m
  • Short-term assets cover short-term liabilities $235m of assets due within a year against $78m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $235m short-term assets against $141m of longer-dated liabilities.
  • More cash than debt $9m of cash against $117m of debt.
  • Debt below 40% of shareholders' equity Debt is 25% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 37% to 25% over five years.
  • A year's operating cash flow covers at least 20% of debt $72m of operating cash flow against $117m of debt.
  • Operating profit covers interest at least five times over Operating income of $96m against $8m of interest.

From UFP Technologies Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+0.2%
year over year
Sales & admin spending
13.3%
of revenue
Days sales outstanding
65 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care supplies
Last 12 months unless stated UFPT ORGO EMBC MDXG ICUI NVST Median
Revenue, last 12 months $632m $457m $1.0bn $304m $2.2bn $2.9bn $1.0bn
Revenue growth, last 12 months 7.3% 6.5% −7.6% −22.8% −9.0% 11.9% 3.4%
Revenue growth, 3-year average 17.8% 0.0% −2.9% −0.6% −2.0% 3.4% 0.0%
Revenue growth, latest quarter 15.1% −56.7% −8.1% −45.2% 0.5% 7.1% 0.6%
Gross margin 28.5% 75.9% 59.0% 77.3% 39.1% 55.2% 52.9%
Operating margin 15.3% −7.8% 21.9% −8.3% 3.3% 9.6% 3.3%
Operating margin, 3-year average 15.4% −5.2% 18.7% 8.0% 2.2% −10.9% 2.2%
Net margin 11.4% −18.4% 8.6% −6.3% 1.4% 3.3% 1.4%
Cash from operations / revenue 11.3% 7.0% 17.1% 6.8% 10.9% 10.6% 10.6%
Free-cash-flow margin 9.0% 4.6% 16.2% 2.0% 6.7% 8.7% 6.7%
Free-cash-flow margin, 3-year average 10.5% −1.4% 9.8% 11.2% 5.2% 10.0% 9.8%
Stock pay / revenue 1.6% 3.1% 2.5% 1.6% 2.5% 1.4% 2.5%
Change in share count 0.2% 1.7% 0.6% −0.9% 2.5% −3.3% −0.4%

Median of all 13 companies we cover in health care supplies. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care supplies companies
Measure Company Peer median Rank
Revenue growth Growth 7.3% 3.4% 3 of 13
Change in growth rate Growth -3.9pp -0.3pp 9 of 13
Gross margin Profitability 28.5% 52.9% 13 of 13
Operating margin Profitability 15.3% 3.3% 3 of 13
Net margin Profitability 11.4% 1.4% 3 of 13
Free-cash-flow margin Cash generation 9.0% 6.7% 5 of 13
Stock pay as % of revenue Cash generation 1.6% 2.5% 6 of 13
Long-term debt as % of assets Balance sheet 15.4% 15.4% 5 of 9
Change in share count Balance sheet 0.2% 0.1% 8 of 12
Days sales outstanding Balance sheet 65 days 65 days 6 of 11

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $591M 98.1% ▲ 20.3%
Engineering and Development $6.9M 1.2% ▲ 47.1%
Tooling and Machinery $4.5M 0.7% ▼ 45.9%

From UFP Technologies Inc's 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.5B
Institutions reporting
278
Shares held vs prior quarter
▲ 8.5%
Positions opened / closed
39 / 33

Top buyers and sellers, Q2 2026: 132 institutions bought and 128 sold ; the biggest buyer was Neuberger Berman Group LLC (+236K shares) and the biggest seller Wasatch Advisors LP (−94K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $303M 1.1M 12.0% ▲ 4.0%
Congress Asset Management Co $182M 687K 7.2% ▲ 31.3%
Wasatch Advisors LP $181M 683K 7.2% ▼ 12.1%
Neuberger Berman Group LLC $142M 537K 5.6% ▲ 78.7%
Price T Rowe Associates Inc $94.7M 357K 3.8% ▲ 45.0%
Boston Trust Walden Corp $89.2M 336K 3.5% ▲ 6.1%
Vanguard Capital Management LLC $87.4M 330K 3.5% ▲ 0.9%
State Street Corp $82.9M 313K 3.3% ▲ 3.1%
American Century Companies Inc $74.2M 280K 2.9% ▲ 122.5%
UBS Group AG $67.5M 255K 2.7% ▲ 46.6%
Thrivent Financial For Lutherans $63.5M 239K 2.5% ▲ 0.9%
Massachusetts Financial Services Co $59.2M 223K 2.3% ▼ 1.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not UFP Technologies Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $14M 27 trades by 7 insiders · 0% under pre-set plans
Net ▼ $14M net selling
Insider Date Trade Shares Price Value
Kozin Marc D Director August 25, 2026 Sell 3,650 $303.97 $1.1M
Kozin Marc D Director August 25, 2026 Sell 3,350 $305.07 $1M
Hudson Symeria Director August 18, 2026 Sell 298 $319.11 $95,095
Hudson Symeria Director August 14, 2026 Sell 1,926 $324.58 $625,141
Feldmann Cynthia L Director August 13, 2026 Sell 1,000 $324.26 $324,260
Bailly R Jeffrey Executive Chairman August 10, 2026 Sell 5,771 $315.53 $1.8M
Bailly R Jeffrey Executive Chairman August 10, 2026 Sell 6,866 $316.58 $2.2M
Bailly R Jeffrey Executive Chairman August 10, 2026 Sell 374 $317.27 $118,659
Bailly R Jeffrey Executive Chairman August 7, 2026 Sell 4,471 $318.21 $1.4M
Bailly R Jeffrey Executive Chairman August 7, 2026 Sell 542 $315.06 $170,763
Holt Jason Vice President August 6, 2026 Sell 1,100 $317.00 $348,700
Bailly R Jeffrey Executive Chairman August 6, 2026 Sell 7,877 $318.12 $2.5M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 3, 2026
  • May 4, 2026
  • February 24, 2026
  • November 3, 2025
  • August 5, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on UFP Technologies Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

UFP Technologies Inc in brief

What does UFP Technologies Inc do?
UFP Technologies Inc is a US-listed company in the health care supplies industry. Its financial year ends in December.
What is UFP Technologies Inc's stock ticker?
UFP Technologies Inc trades under the ticker UFPT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is UFP Technologies Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, UFP Technologies Inc reported revenue of $632M, 7.3% higher than a year earlier, according to its SEC filings.
What is UFP Technologies Inc's free cash flow?
UFP Technologies Inc's free-cash-flow margin is 9.0% of revenue over the trailing twelve months, ranking 5 of the 13 health care supplies companies we cover.
What is UFP Technologies Inc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of UFP Technologies Inc's free cash flow after stock-based pay gives ~$220 per share in the base case, and ~$160–$300 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are UFP Technologies Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Congress Asset Management Co and Wasatch Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is UFP Technologies Inc's market cap?
On November 2, 2026, UFP Technologies Inc's market capitalisation was about $2.2B, with a price-to-earnings ratio of 30.7 and net debt of $108M. Market figures come from third-party market data and may be delayed.
How much debt does UFP Technologies Inc have?
UFP Technologies Inc's debt-to-equity ratio is 25.4%, from its latest balance sheet (36.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are UFP Technologies Inc's competitors?
In our Health Care Supplies peer group, the companies closest to UFP Technologies Inc are Organogenesis Holdings Inc., Embecta Corp., Mimedx Group, Inc., ICU Medical Inc and Envista Holdings Corp. The side-by-side comparison below sets their revenue, margins and growth against UFP Technologies Inc's.
Are insiders buying or selling UFP Technologies Inc stock?
Over the last 12 months, UFP Technologies Inc's directors and officers reported 0 open-market purchases and 27 sales on Form 4. The insider trading page charts every trade.
When is UFP Technologies Inc's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — UFP Technologies Inc announces its own schedule.